IP Verse

Method To Improve Virus Removal In Protein Purification - EP2462158

The patent EP2462158 was granted to F Hoffmann LA Roche on Jan 10, 2018. The application was originally filed on Aug 6, 2010 under application number EP10740823A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2462158

F HOFFMANN LA ROCHE
Application Number
EP10740823A
Filing Date
Aug 6, 2010
Status
Granted And Under Opposition
Dec 8, 2017
Grant Date
Jan 10, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BAYER GMBHBAYER PHARMA AKTIENGESELLSCHAFTBAYER ANIMAL HEALTHOct 10, 2018BIP PATENTSADMISSIBLE
LEEMINGOct 10, 2018J A KEMPADMISSIBLE
MAIWALDOct 10, 2018MAIWALDADMISSIBLE
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBOct 10, 2018MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBADMISSIBLE
MORPHOSYSOct 10, 2018SPILLERADMISSIBLE
NEUEFEINDOct 10, 2018MAIWALDADMISSIBLE
POHLMANOct 10, 2018POHLMANADMISSIBLE
STRAWMANOct 10, 2018MURGITROYDADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEOct 9, 2018KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
POTTER CLARKSONOct 9, 2018POTTER CLARKSONADMISSIBLE
GRUNECKER PATENT UND RECHTSANWALTE PARTG MBBOct 4, 2018GRUNECKER PATENTADMISSIBLE

Patent Citations (59) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0003089
DESCRIPTIONEP0404097
DESCRIPTIONUS4399216
DESCRIPTIONUS4676980
DESCRIPTIONUS4816567
DESCRIPTIONUS4975278
DESCRIPTIONUS5500362
DESCRIPTIONUS5545806
DESCRIPTIONUS5545807
DESCRIPTIONUS5569825
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5641870
DESCRIPTIONUS5661016
DESCRIPTIONUS5821337
DESCRIPTIONUS7118675
DESCRIPTIONWO8101145
DESCRIPTIONWO8807378
DESCRIPTIONWO8905859
DESCRIPTIONWO9100360
DESCRIPTIONWO9220373
DESCRIPTIONWO9308829
DESCRIPTIONWO9311161
DESCRIPTIONWO9404690
DESCRIPTIONWO9627011
INTERNATIONAL-SEARCH-REPORTUS2003146156
INTERNATIONAL-SEARCH-REPORTWO2007108955
INTERNATIONAL-SEARCH-REPORTWO2009017491
OPPOSITIONEP1403274
OPPOSITIONEP1577319
OPPOSITIONEP1614693
OPPOSITIONEP2281000
OPPOSITIONEP2435474
OPPOSITIONEP2473617
OPPOSITIONJPH02198687
OPPOSITIONJPH07116484
OPPOSITIONUS2003036638
OPPOSITIONUS2003146156
OPPOSITIONUS2003229212
OPPOSITIONUS2004241878
OPPOSITIONUS2006257972
OPPOSITIONUS2009148443
OPPOSITIONUS5629084
OPPOSITIONUS6177548
OPPOSITIONUS7001550
OPPOSITIONUS7118675
OPPOSITIONUS7847071
OPPOSITIONWO03066669
OPPOSITIONWO03102132
OPPOSITIONWO2005073367
OPPOSITIONWO2006042541
OPPOSITIONWO2007108955
OPPOSITIONWO2008025747
OPPOSITIONWO2008036899
OPPOSITIONWO2008073620
OPPOSITIONWO2009017491
OPPOSITIONWO2009085765
OPPOSITIONWO2010138736
OPPOSITIONWO2011031397

Non-Patent Literature (NPL) Citations (159) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, no. 1, pages 86 - 95-
DESCRIPTION- BOHONAK; ZYDNEY, JOURNAL OF MEMBRANE SCIENCE, (2005), vol. 254, no. 1-2, pages 71 - 79-
DESCRIPTION- BOLTON ET AL., APPL. BIOCHEM., (2006), vol. 43, pages 55 - 63-
DESCRIPTION- BOLTON ET AL., BIOTECHNOL. APPL. BIOCHEM., (2006), vol. 43, pages 55 - 63-
DESCRIPTION- BOLTON ET AL., BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, (2005), vol. 42, pages 133 - 142-
DESCRIPTION- BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81-
DESCRIPTION- BROWN, DEV. BIOL. STAND., (1993), vol. 81-
DESCRIPTION- BRUGGERMANN ET AL., YEAR IN IMMUNO., (1993), vol. 7, page 33-
DESCRIPTION- CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34-
DESCRIPTION- CARTER ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 4285-
DESCRIPTION- CHOTHIA, C. ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917-
DESCRIPTION- CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, page 901-
DESCRIPTION- CHU; ROBINSON, CURRENT OPINION IN BIOTECHNOLOGY, (2001), vol. 12, pages 180 - 187-
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628-
DESCRIPTION- CLYNES ET AL., PNAS USA, (1998), vol. 95, pages 652 - 656-
DESCRIPTION- CURTIS ET AL., BIOTECHNOLOGY AND BIOENGINEERING, (2003), vol. 84, no. 2, pages 179 - 186-
DESCRIPTION- DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 41-
DESCRIPTION- FISHWILD ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 51-
DESCRIPTION- GARNICK, DEV BIOL STAND. BASEL: KARGER, (1998), vol. 93, pages 21 - 29-
DESCRIPTION- GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163-
DESCRIPTION- GRAHAM ET AL., VIROLOGY, (1978), vol. 52, pages 456 - 457-
DESCRIPTION- GRUBER ET AL., J. IMMUNOL., (1994), vol. 152, page 5368-
DESCRIPTION- GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587-
DESCRIPTION- HIRASAKI ET AL., POLYMER JOURNAL, (1994), vol. 26, no. 11, pages 1244 - 1256-
DESCRIPTION- HOLLINGER ET AL., PROC. NATL. ACAD SCI. USA, (1993), vol. 90, pages 6444 - 6448-
DESCRIPTION- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448-
DESCRIPTION- HOOGENBOOM ET AL., J. MOL. BIOL., (1991), vol. 227, page 381-
DESCRIPTION- HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381-
DESCRIPTION- JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258-
DESCRIPTION- JAKOBOVITS ET AL., PROC. NATL. ACAD SCI. USA, (1993), vol. 20, page 2551-
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525-
DESCRIPTION- KIM ET AL., J. IMMUNOL., (1994), vol. 24, page 249-
DESCRIPTION- KINET, ANNU. REV. IMMUNOL., (1991), vol. 9, pages 457 - 92-
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, page 495-
DESCRIPTION- KOSTELNY ET AL., J. IMMUNOL., (1992), vol. 148, no. 5, pages 1547 - 1553-
DESCRIPTION- KOWER ET AL., NATURE, (1975), vol. 256, page 495-
DESCRIPTION- KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001-
DESCRIPTION- LIEBER ET AL., SCIENCE, (1973), vol. 182, pages 56 - 59-
DESCRIPTION- LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859-
DESCRIPTION- LONBERG; HUSZAR, INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93-
DESCRIPTION- LUBINIECKI ET AL., DEV BIOL STAND, (1989), vol. 70, pages 187 - 191-
DESCRIPTION- MARKS ET AL., BIOFFECHNOLOGY, (1992), vol. 10, pages 779 - 783-
DESCRIPTION- MARKS ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 779 - 783-
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581-
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597-
DESCRIPTION- MASSEY, NATURE, (1987), vol. 328, pages 457 - 458-
DESCRIPTION- MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554-
DESCRIPTION- M. DAëRON, ANNU. REV. IMMUNOL., (1997), vol. 15, pages 203 - 234-
DESCRIPTION- MILLSTEIN ET AL., NATURE, (1983), vol. 305, pages 537 - 539-
DESCRIPTION- MORRISON ET AL., PROC. NATL ACAD. SCI. USA, (1984), vol. 81, page 6851-
DESCRIPTION- MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855-
DESCRIPTION- MORRISON, NATURE, (1994), vol. 368, pages 812 - 13-
DESCRIPTION- MUNSON ET AL., ANAL. BIOCHEM., (1980), vol. 107, page 220-
DESCRIPTION- MUNSON; POLLARD, ANAL. BIOCHEM., (1980), vol. 107, page 220-
DESCRIPTION- NEUBERGER ET AL., NATURE, (1984), vol. 312, pages 604 - 608-
DESCRIPTION- NEUBERGER, NATURE BIOTECHNOLOGY, (1996), vol. 14, page 826-
DESCRIPTION- OMAR; KEMPF, TRANSFUSION, (2002), vol. 42, no. 8, pages 1005 - 1010-
DESCRIPTION- PLIICKTHUN, IMMUNOL. REVS., (1992), vol. 130, pages 151 - 188-
DESCRIPTION- PRESTA, CURR. OPIN. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596-
DESCRIPTION- PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596-
DESCRIPTION- PRESTA ET AL., J. IMMNOL., (1993), vol. 151, page 2623-
DESCRIPTION- RAVETCH; KINET, ANNU. REV. IMMUNOL., (1991), vol. 9, pages 457 - 92-
DESCRIPTION- REICHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329-
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327-
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329-
DESCRIPTION- SHALABY ET AL., J. EXP. MED., (1992), vol. 175, pages 217 - 225-
DESCRIPTION- SHAW ET AL., GENE, (1983), vol. 23, page 315-
DESCRIPTION- SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296-
DESCRIPTION- SKERRA ET AL., CURR. OPINION IN IMMUNOL., (1993), vol. 5, pages 256 - 262-
DESCRIPTION- SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210-
DESCRIPTION- THOMAS, LANCET, (1994), vol. 343, pages 1583 - 1584-
DESCRIPTION- TRAUNECKER ET AL., EMBO J., (1991), vol. 10, pages 3655 - 3659-
DESCRIPTION- TUTT ET AL., J. IMMUNOL., (1991), vol. 147, page 60-
DESCRIPTION- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536-
DESCRIPTION- WATERHOUSE ET AL., NUC. ACIDS. RES., (1993), vol. 21, pages 2265 - 2266-
DESCRIPTION- ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062-
OPPOSITION- Antibody Purification Handbook, (20020000), pages 1 - 112-
OPPOSITION- BROWN A., "Use of charged membrane to identify soluble protein foulants in order to facilitate parvovirus filtration", In IBC's 20th antibody development and production conference, San Diego , CA, (20080000), pages 1 - 38, XP055525592-
OPPOSITION- BROWN et al., "Use of Charged Membranes to Identify Soluble Protein Foulants in order to Facilitate Parvovirus Filtration", IBC's 20th Antibody Development and Production, San Diego , CA, (20080000), pages 1 - 38, XP055525592-
OPPOSITION- BURNOUF et al., "Place of Nanofiltration for Assuring Viral Safety of Biologicals", Current Nanoscience, (20050000), vol. 1, pages 189 - 201, XP055525664-
OPPOSITION- "chapter 16", GHOSE et al., Process Scale Bioseparations for the Biopharmaceuticals Industry, (20070000), vol. 16, pages 464 - 489, XP055525638-
OPPOSITION- "Chapter 17", GAGNON, process scale bioseparations for the biopharmaceutical industry, (20070000), pages 491 - 505, XP055525643-
OPPOSITION- GAGNON et al., "A Ceramic Hydroxyapatite-Based Purification Platform Simultaneous Removal of Leached Protein A", Aggregates, DNA, and Endotoxins from MAbs, BioProcess International, (20060201), pages 50 - 60, XP008147376-
OPPOSITION- GOTTSCHALK, U., "Downstream Processing", Filtration and Purification in the Biopharmaceutical Industry, (20080000), pages 459 - 493, XP055609138-
OPPOSITION- Graver Technologies. Powdex® selection guide-
OPPOSITION- HOFFMANN, "Outsourcing Manufacturing of Biopharmaceuticals", Beoringer Ingelheim Mastering Flexibility, (20090302), pages 1 - 20, XP055524131-
OPPOSITION- "Impact of Lot-to-Lot Variability of Cation Exchange Chromatography Resin on Process Performance", BioPharm International, (20080501), vol. 21, no. 5, XP007919781-
OPPOSITION- IRELAND et al., "Optimizing virus filter performance with prefiltration", BioProcess Int, (20051100), vol. 10, pages 44 - 47, XP055525974-
OPPOSITION- IRELAND , T. et al., "Optimizing virus filter performance with prefiltration", BioProcess Int., (20050000), vol. 3, no. 10, pages 44 - 47, XP055525974-
OPPOSITION- KASTNER et al., Protein liquid chromatography, (20000000), vol. 61-
OPPOSITION- KATZ A. et al., "prefiltration and proces improvments enhancing virus filter performance with the use of adsorptive depth oe surface modified prefilters", Millipore sigma, (20160000), URL: http://www.bioprocessintl.com/poster - hall/prefi l tration - proccss- improvements-enhancing-virus-filter-performance-use-adsorptive- depth -surface- modified-prefil ters, XP055525581-
OPPOSITION- KERN G et al., "Virus removal by filtration: points to consider", BioPharm, (20061001), vol. 19, no. 10, XP055525611-
OPPOSITION- KIM et al., "Removal and Inactivation of Viruses During the Manufacture of a High- purity Antihemophilic Factor IX from Human Plasma", Biotechnology and Bioprocess Engineering, vol. 14, (20090000), pages 716 - 724, (20100114), XP055523023-
OPPOSITION- LI et al., "CHAPTER 9: DEVELOPMENT OF A PLATFORM PROCESS FOR THE PURIFICATIONOF THERAPEUTIC MONOCLONAL ANTIBODIES", LI et al., LI et al., Process Scale Purifi- cation of Antibodies, (20080815), pages 187 - 201, XP055525910-
OPPOSITION- LI et al., "Development of a platform process for the purification of therapeutic monoclonal antibodies", LI et al., Li et al., Process Scale Purification of Antibodies, (20090000), pages 187 - 201, XP055525910-
OPPOSITION- MEHTA, A. et al., "Purifying Therapeutic Monoclonal Antibodies", Chemical Engineering Progress, (20080000), vol. 104, no. 5, pages S14 - S20, XP055162785-
OPPOSITION- MEHTA et al., "Purifying Therapeutic Monoclonal Antibodies", Chemical engineering progress,, (20080000), pages S14 - S20, XP055162785-
OPPOSITION- MEHTA et al., "Purifying Therapeutic Monoclonal Antibodies", Chemical Engineering Progress, (20080000), vol. 104, no. 5, pages S14 - S20, XP055315439-
OPPOSITION- Millipore Corporation. Millistak+® Pod Disposable Depth Filter System, (20090400), pages 1 - 4-
OPPOSITION- "Mixed-bed ion-exchange of proteins", PolyLC inc, Columbia, MD, (20080200), pages 1 - 2, XP055526422-
OPPOSITION- Monolithic materials: preparation , properties and applications, (20030000), vol. 67, page 216-
OPPOSITION- "Optimizing viral clearance processes - Ensuring product quality, yield and safety using Viresolve NFP filters", Millipore Corporation., Billerica, MA, (20031200), XP055525958-
OPPOSITION- "parvoviridae", Stedman's Medical Dictionary, (20000000), page 1329, XP055526315-
OPPOSITION- Pattison ET AL, "CHAPTER 64", Medical Microbioloqy, ( ), URL: https://www.ncbi.nlm.nih.gov/books/NBK8545/, XP055525918-
OPPOSITION- PÉROLA O., "Methods of Endotoxin Removal from Biological Preparations", J Pharm Pharmaceut Sci, vol. 10, no. 3, (20070000), pages 388 - 404, URL: www. cspsCanada.org, XP007913761-
OPPOSITION- P. GAGNON et al., "A Ceramic Hydroxyapatite Based Purification Platform. Simultaneous Removal of Leached Protein A, Aggregates, DNA and Endotoxins from MAbs", BioProcess International, (20060000), vol. 4, pages 50 - 60, XP008147376-
OPPOSITION- "product information Viresolve pro+ solution", mollipore corporation, (20090300), XP055525573-
OPPOSITION- THÖMMES et al., "Alternatives to packed-bed chromatography for antibody extraction and purification", Process Scale Purification of Antibodies, (20090000), pages 293 - 308, XP055609158-
OPPOSITION- TIPTON, BARBARA et al., "Retrovirus and parvovirus clearance from an affinity column product using adsorptive depth filtration", BIOPHARM-EUGENE, (20020900), vol. 15.9, pages 43 - 50, XP055525673-
OPPOSITION- TIPTON et al., "Retrovirus and Parvovirus Clearance from an Affinity Column Product Using Adsorptive Depth Filtration", Biopharm, (20020000), pages 43 - 50, XP055525673-
OPPOSITION- VENTANI et al., "Antibody Purification Using Membrane Adsorbers", BioPharm International, (20091002), vol. 2009, XP055524148-
OPPOSITION- "Virus Purification and Removal", Sartorius Technical Note, URL: https://www.sartoriusglobal.com/mediafile/Appl_Sartobind_Virus_Purification___Removal_SL-4038-e.pdf-
OPPOSITION- Wheaton et al, "DOWEX Ion exchange resins - Fundamentals of ion exchange", dow chemical usa, (20000600), pages 1 - 9, XP002606300-
OPPOSITION- "Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities", BRIAN KELLEY PHD et al., Process Scale Purification of Antibodies, Uwe Gottschalk John Wiley & Sons , Inc., (20080815), pages 1 - 24, XP055027823
OPPOSITION- GOTTSCHALK, "Downstream processing of monoclonal antibodies: from high dilution to high purity", BioPharm International, (20050601), vol. 18, no. 6, pages 1 - 11, XP055027823
OPPOSITION- KELLEY, B. et al., "Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities", Process Scale Purification of Antibodies, (20090000), pages 1 - 23, XP055027823
OPPOSITION- KELLEY et al., "DOWNSTREAM PROCESSING OF MONOCLONAL ANTIBODIES: CURRENT PRACTICES AND FUTURE OPPORTUNITIES", Process Scale Pu- rification of Antibodies, (20080815), pages 1 - 24, XP055027823
OPPOSITION- GHOSE, S. et al., "Integrated Polishing Steps for Monoclonal Antibody Purification", Process Scale Purification of Antibodies, (20090000), pages 145 - 167, XP055609148
OPPOSITION- ZHOU, "Orthogonal virus clearance applications in monoclonal antibody production", Process Scale Purification of Antibodies, (20090000), pages 169 - 186, XP055609159
OPPOSITION- BAKHSHAYESHI et al., "Effect of Solution pH on Protein Transmission and Membrane Capacity During Virus Filtration", Biotecnol. Bioeng., (20070000), vol. 100, no. 1, pages 108 - 117, XP055524153
OPPOSITION- BROWN, ARICK et al., "Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre-filtration", Biotechnology and bioengineering, (20100300), vol. 106, no. 4, pages 627 - 637, XP008150356
OPPOSITION- BROWN et al., "Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre-filtration", Biotechnol. Bioeng., (20100312), vol. 106, no. 4, pages 627 - 637, XP008150356
OPPOSITION- BROWN et al., "Increasing Parvovirus Filter Throughput of Monoclonal Antibodies Using Ion Exchange Membrane Adsorptive Pre-filtration", Biotechnology and Bioengineering, (20100701), vol. 106, no. 4, XP008150356
OPPOSITION- BROWN et al., "Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre-filtration", Biotechnoloqv and Bioenqineer- inq., (20100312), vol. 106, no. 4, pages 627 - 637, XP008150356
OPPOSITION- RIORDAN et al., "Salt Tolerant Membrane Adsorbers for Robust Impurity Clearance", Biotechnol. Prog., (20090902), vol. 25, no. 6, pages 1695 - 1702, XP055524161
OPPOSITION- SOMMERFELD et al., "Challenges in biotechnology production-generic processes and process optimization for monoclonal antibodies", Chem Eng, (20050523), vol. 44, pages 1123 - 1137, XP004922715
OPPOSITION- ISHIHARA et al., "Accelerated purification process development of monoclonal antibodies for shortening time to clinic", Journal of Chromatog- raphy A, (20071107), vol. 1176, pages 149 - 156, XP022373481
OPPOSITION- ISHIHARA T., "Accelerated purification process development 01. 07. November of monoclonal antibodies for shortening time to clinic. Design and case study of chromatography processes", Kadoya Toshihiko, Journal of Chromatography A, (20070000), vol. 1176, pages 149 - 156, XP022373481
OPPOSITION- SHUKLA, A. A. et al., "Downstream processing of monoclonal antibodies-Application of platform approaches", J Chromatography B, (20070000), vol. 848, pages 28 - 39, XP005922825
OPPOSITION- SHUKLA, ABHINAV A. et al., "Downstream processing of monoclonal antibodies- application of platform approaches", Journal of Chromatography B, (20061000), vol. 848, no. 1, pages 28 - 39, XP005922825
OPPOSITION- SHUKLA et al., "Downstream processing of monoclonal 13. October 2006 antibodies - Application of platform approaches", Journal of Chromatography B, (20070000), vol. 848, pages 28 - 39, XP005922825
OPPOSITION- SHUKLA et al., "Downstream processing of monoclonal antibodies-Application of platform approaches", J. Chomatog. B, (20070000), vol. 848, pages 28 - 39, XP005922825
OPPOSITION- SHUKLA et al., "Downstream processing of monoclonal antibodies - Application of platform approaches", Journal of Chromatography B, (20060000), vol. 848, doi:10.1016/j.jchromb.2006.09.026, pages 28 - 39, XP002744086
OPPOSITION- BOHONAK, D. M. et al., "Compaction and permeability effects with virus filtration membranes", J. Membrane Sci., (20050000), vol. 254, pages 71 - 79, XP004884923
OPPOSITION- BOHONAK et al., "Compaction and permeability effects with virus filtration membranes", Journal of Membrane Science, (20050000), vol. 254, doi:10.1016/j.memsci.2004.12.035, pages 71 - 79, XP004884923
OPPOSITION- VAN REIS et al., "Bioprocess membrane technology", J. Membrane Sci., (20070000), vol. 297, pages 16 - 50, XP055523013
OPPOSITION- VAN REIS et al., "Bioprocess membrane technology", Journal of Membrane Science, (20070000), vol. 297, pages 16 - 50, XP055523013
OPPOSITION- VAN REIS et al., "Bioprocess membrane technology", Journal of Membrane Science, (20070300), vol. 297, no. 1-2, pages 16 - 50, XP055523013
OPPOSITION- VAN REIS et al., "Bioprocess membrane technology", Journal of Membrane Science, vol. 297, (20070000), pages 1 - 35, (20070705), XP055523013
OPPOSITION- CHEN et al., "Factors affecting endotoxin removal from recombinant therapeutic proteins by anion exchange chromatography", Protein Expr Purif., (20081022), vol. 64, no. 1, pages 76 - 81, XP025801456
OPPOSITION- MOTOYAMA , AKIRA et al., "Anion and cation mixed-bed ion exchange for enhanced multidimensional separations of peptides and phosphopeptides", Analytical chemistry, (20070400), vol. 79, no. 10, pages 3623 - 3634, XP055525941
OPPOSITION- Gottschalk, "Bioseparation in Antibody Manufacturing: The Good, The Bad and The Ugly", Biotechol. Prog., vol. 24, (20080000), pages 496 - 503, (20080429), XP002585902
OPPOSITION- GOTTSCHALK U., "Bioseparation in Antibody Manufacturing: The Good, The Bad and The Ugly", Biotechnol. Prog., (20080000), vol. 24, pages 496 - 503, XP002585902
OPPOSITION- WURM, "Production of recombinant protein therapeutics in cultivated mammalian cells", Nat Biotechnol., (20040000), vol. 22, no. 11, pages 1393 - 8, XP002514352
OPPOSITION- BOLTON et al., "Normal-flow virus filtration: detection and assessment of the endpoint in bioprocessing", Biotechnology Applied Biochemistry, (20050000), vol. 42, doi:10.1042/BA20050056, pages 133 - 142, XP055526312
OPPOSITION- BOLTON, G. et al., "Normal-flow virus filtration: detection and assessment of theendpoint in bioprocessing", Biotechnol. Appl. Biochem., (20050000), vol. 42, no. 2, pages 133 - 142, XP055526312
OPPOSITION- BOLTON et al., "Increasing the capacity of parvovirus-retentive membranes: performance of the Viresole? prefilter", Biotechnology Applied Biochemistry, (20060000), vol. 43, doi:10.1042/BA20050108, pages 55 - 63, XP009076699
OPPOSITION- BOLTON et al., "INCREASING THE CAPACITY OF PARVOVIRUS-RETENTIVE MEMBRANES: PERFORMANCE OF THE VIRESOLVE (TM) PREFILTER", Biotechnology and Applied Biochemistry, (20060000), vol. 43, pages 55 - 63, XP009076699
OPPOSITION- BOLTON, G. et al., "INCREASING THE CAPACITY OF PARVOVIRUS-RETENTIVE MEMBRANES: PERFORMANCE OF THE VIRESOLVE (TM) PREFILTER", Biotechnol. Appl. Biochem., (20060000), vol. 43, pages 55 - 63, XP009076699
OPPOSITION- FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Process", Biotechnology and Genetic Engineering Reviews, (20010000), vol. 18, no. 1, doi:10.1080/02648725.2001.0648017, pages 301 - 327, XP008034714
OPPOSITION- FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotech. Gen. Eng. Rev., (20010000), vol. 18, pages 301 - 327, XP008034714
OPPOSITION- FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", BIOTECH. GEN. ENG. REV., (20010000), vol. 18, pages 301 - 327, XP008034714
OPPOSITION- FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotechnology and Genetic Engineering Reviews, (20010000), vol. 18, pages 301 - 329, XP008034714
OPPOSITION- FAHRNER, R. L. et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotechnol. Genet. Eng. Rev., (20010000), vol. 18, pages 301 - 327, XP008034714
OPPOSITION- ROBERT L. FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotechnology and Genetic Engineering Reviews, (20010000), vol. 18, no. 1, pages 301 - 327, XP008034714
OPPOSITION- HENRIE M. et al., "in vitro assessment of dialysis membrane as an endotoxin transfer barrier geometry monphology and permeability", Artif. Organs, (20080000), vol. 32, no. 9, pages 701 - 710, XP055525586
OPPOSITION- LI, F. et al., "Current Therapeutic Antibody Production and Process Optimization", BioProcessing J., (20050000), vol. 4, no. 5, pages 23 - 30, XP055521823
OPPOSITION- KELLEY et al., "Industrialization of mAb production technology: The bioprocessing industry at a crossroads", mAbs, (20090900), vol. 1, no. 5, doi:10.4161/mabs.1.5.9448, pages 443 - 452, XP055344464
OPPOSITION- HUI F. LIU et al., "Recovery and purification process development for monoclonal antibody production", mAbs, (20100000), vol. 2, no. 5, pages 480 - 499, XP055027612

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents